Record Information |
---|
Version | 2.0 |
---|
Creation Date | 2014-09-11 02:05:05 UTC |
---|
Update Date | 2014-12-24 20:26:55 UTC |
---|
Accession Number | T3D4690 |
---|
Identification |
---|
Common Name | Dichloroacetic Acid |
---|
Class | Small Molecule |
---|
Description | Dichloroacetic acid, often abbreviated DCA, is an acid analogue of acetic acid in which two of the three hydrogen atoms of the methyl group have been replaced by chlorine atoms. The salts and esters of dichloroacetic acid are called dichloroacetates. Salts of DCA are used as drugs since they inhibit the enzyme pyruvate dehydrogenase kinase. Early reports of its activity against brain cancer cells led patients to treat themselves with DCA, which is commercially available in non-pharmaceutical grade. A phase 1 study in 5 patients concluded that DCA was safe, but wasn't designed to establish effectiveness. |
---|
Compound Type | - Drug
- Household Toxin
- Organic Compound
- Organochloride
- Synthetic Compound
|
---|
Chemical Structure | |
---|
Synonyms | Synonym | DCA | Dichloroacetate | dichloroacetate | Dichloroacetic acid |
|
---|
Chemical Formula | C2H2Cl2O2 |
---|
Average Molecular Mass | 128.942 g/mol |
---|
Monoisotopic Mass | 127.943 g/mol |
---|
CAS Registry Number | 79-43-6 |
---|
IUPAC Name | 2,2-dichloroacetic acid |
---|
Traditional Name | dichloroacetic acid |
---|
SMILES | OC(=O)C(Cl)Cl |
---|
InChI Identifier | InChI=1S/C2H2Cl2O2/c3-1(4)2(5)6/h1H,(H,5,6) |
---|
InChI Key | InChIKey=JXTHNDFMNIQAHM-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as alpha-halocarboxylic acids. These are carboxylic acids containing a halogen atom bonded to the alpha carbon atom. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Alpha-halocarboxylic acids and derivatives |
---|
Direct Parent | Alpha-halocarboxylic acids |
---|
Alternative Parents | |
---|
Substituents | - Alpha-halocarboxylic acid
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Organochloride
- Organohalogen compound
- Carbonyl group
- Alkyl halide
- Alkyl chloride
- Aliphatic acyclic compound
|
---|
Molecular Framework | Aliphatic acyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Exogenous |
---|
Cellular Locations | |
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | Not Available |
---|
Biological Roles | Not Available |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Liquid |
---|
Appearance | Not Available |
---|
Experimental Properties | Property | Value |
---|
Melting Point | 13.5°C | Boiling Point | 194°C | Solubility | 1E+006 mg/L (at 20°C) | LogP | 0.92 |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | Deposition Date | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2022-08-08 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QQ , negative | splash10-0059-6900000000-9d33b2f109bd8208b818 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QQ , negative | splash10-001i-9000000000-cdde3faa793ecb51af1b | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QQ , negative | splash10-001i-9000000000-c1ded91474fde2787d95 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QQ , negative | splash10-0019-9000000000-cea4fe3c3f1653aa150d | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QQ , negative | splash10-000i-9000000000-68d75216c4534c61a4b4 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QQ , negative | splash10-0059-6900000000-55338ed4fe8335b6f8ba | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QQ , negative | splash10-001i-9000000000-d0c2081f59cf4a1d9bb9 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QQ , negative | splash10-001i-9000000000-aa8cfce9c157e8ce5c26 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QQ , negative | splash10-0019-9000000000-d0fd266005ba1e11af9f | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QQ , negative | splash10-000i-9000000000-67e8e2a12579c484a9d1 | 2017-09-14 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-004i-0900000000-2c591b536e9b1cdd5103 | 2016-08-01 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-004i-0900000000-e235e740081767bebeb0 | 2016-08-01 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-03ec-7900000000-19ec9f5725beb405a85f | 2016-08-01 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-004i-0900000000-9824d7737d8edd5c640c | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-004i-1900000000-047b42b607987ffb5cba | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-004i-1900000000-d56ccde35fe241d821f6 | 2016-08-03 | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-0002-9000000000-5cc2c87638085fad9afc | 2014-09-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, experimental) | Not Available | 2014-09-20 | View Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Ingestion |
---|
Mechanism of Toxicity | The dichloroacetate ion stimulates the activity of the enzyme pyruvate dehydrogenase by inhibiting the enzyme pyruvate dehydrogenase kinase. Thus, it decreases lactate production by shifting the metabolism of pyruvate from fermentation towards oxidation in the mitochondria. (Wikipedia) |
---|
Metabolism | Dichloroacetic acid is metabolized in the liver by oxidative dechlorination to yield glyoxylate, which can enter intermediary metabolism and either be oxidized to oxalate and excreted, converted to carbon dioxide, and/or incorporated into amino acids or other cellular molecules. (3) |
---|
Toxicity Values | ORAL (LD50): Acute: 2820 mg/kg [Rat]; DERMAL (LD50): Acute: 510 mg/kg [Rabbit] |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | 2B, possibly carcinogenic to humans. (4) |
---|
Uses/Sources | Dichloroacetic acid has shown promise as a potentially new class of anti-cancer medication, but has yet to complete clinical trials. Early reports of its activity against brain cancer cells led patients to treat themselves with DCA, which is commercially available in non-pharmaceutical grade. As of October 2014, dichloroacetic acid was undergoing phase III clinical trials for cancer treatment (1) (Wikipedia). Dichloroacetic acid has undergone clinical trials for the treatment of lactic acidosis in humans, but the trials found no clinical benefit (Wikipedia). In 2014 Thomas E. Mallouk and colleagues published a new technique for the production of graphene by intercalation of graphite with non-oxidizing Brønsted acids including dichloroacetic acid, raising the prospect that dichloroacetic acid might be used in industrial graphene production in the future (2). |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | Multiple independent studies demonstrate that DCA has the ability to alter normal carbohydrate metabolism. Dichloroacetic acid treatment results in a significant reduction in plasma levels of glucose, pyruvate, and lactate. Another consistent finding in DCA ingestion studies is a dose-related increase in liver size, generally accompanied (or caused) by an increase in glycogen deposition in the liver. There is an extensive and consistent data base demonstrating the reproductive toxicity of DCA in males and females. Neurologic symptoms and morphologic changes in the nervous system have been reported in humans, dogs, and rats. (3) |
---|
Symptoms | Not Available |
---|
Treatment | Not Available |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB08809 |
---|
HMDB ID | Not Available |
---|
PubChem Compound ID | 6597 |
---|
ChEMBL ID | CHEMBL13960 |
---|
ChemSpider ID | 10771217 |
---|
KEGG ID | C11149 |
---|
UniProt ID | Not Available |
---|
OMIM ID | |
---|
ChEBI ID | 36386 |
---|
BioCyc ID | Not Available |
---|
CTD ID | Not Available |
---|
Stitch ID | Not Available |
---|
PDB ID | Not Available |
---|
ACToR ID | Not Available |
---|
Wikipedia Link | Dichloroacetic_acid |
---|
References |
---|
Synthesis Reference | Joanne D. Burger, William L. Howard, “Method for preparing pentachloroacetone and dichloroacetic acid from isopropyl ethers.” U.S. Patent US3996272, issued August, 1968. |
---|
MSDS | T3D4690.pdf |
---|
General References | - American Cancer Society - Dichloroacetate (DCA) [Link]
- Nina I. Kovtyukhova, Yuanxi Wang, Ayse Berkdemir, Rodolfo Cruz-Silva, Mauricio Terrones, Vincent H. Crespi & Thomas E. Mallouk. Non-oxidative intercalation and exfoliation of graphite by Brønsted acids. Nature Chemistry (2014), published online 07 September 2014. doi:10.1038/nchem.2054. [Link]
- US EPA - Toxicological Review of Dichloroacetic Acid (August 2003) [Link]
- International Agency for Research on Cancer (2014). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. [Link]
|
---|
Gene Regulation |
---|
Up-Regulated Genes | Not Available |
---|
Down-Regulated Genes | Not Available |
---|